ADE-G3-based cream rapidly soothes sensitive facial skin

Key takeaways:

• After the first application, 93% of subjects reported an immediate skin soothing effect.
• Physicians observed that xerosis severity and dermatological-related quality of life impairment also improved.

ADE-G3-based cream was efficacious and well tolerated in adults with sensitive facial skin, according to a study.

“Sensitive or reactive skin is a common dermatological problem in the general population, with prevalence estimates from self-reporting surveys indicating that approximately 60% to 70% of women and 50% to 60% of men are affected,” Andreas Wollenberg, MD, professor of dermatology and allergy at Ludwig Maximilian University of Munich and consultant dermatologist at University Hospital Augsburg in Germany, and colleagues wrote.

The authors also explained that individuals with sensitive skin usually display at least one of the following changes: impaired skin barrier function, an increased immune response and over-reactive cutaneous nerve endings or neurogenic inflammation.

An extract called ADE-G3 (D-Sensinose, Avéne), which is derived from the bacterium Aquaphilus dolomiae, may have an ability to address these issues, including neurogenic skin inflammation and skin barrier disfunction.

To investigate, researchers conducted a real-world, prospective, observational study. The study included 2,382 subjects (mean age, 42 years; 79.2% women) across 13 countries and occurred from September 2021 to November 2022. Each subject used an ADE-G3-based cream once or twice daily for 2 to 3 months and subsequently reported changes in their symptoms via a self-administered questionnaire. Physicians also assessed changes in xerosis severity, overall product effectiveness and tolerability.

After the first ADE-G3-based cream application, 93% of subjects reported an immediate skin soothing effect. After using the product for a mean of 9 days, 94% of subjects reported improvements in skin sensitivity symptoms.

Observing physicians reported that after subjects used ADE-G3-based cream for a mean 72 ± 21 days, xerosis severity decreased by a mean 72% and dermatological-related quality of life impairment was reduced by a mean 78% (P < .001 for both).

By the end of the study, 92% of subjects were satisfied with the cream and 95% believed the product improved their overall skin condition. Physicians concurred, reporting that the cream was effective for 92% of subjects and well tolerated by 98%.

“This real-world international study demonstrated that the postbiotic ADE-G3-based cream was an effective topical solution for sustainably soothing sensitive skin, calming skin discomfort and controlling skin hyper-reactivity, regardless of the factors initially contributing to the skin sensitivity,” the authors concluded.